The usual key to the quarterly earnings is the amount of cash and cash equivalents available to sustain the organization through the new few Q’s or “runway”.
What matters beyond the spending … are the significant milestones and catalysts in furthering clinical development and trials… and if they have the cash to advance their vision and focus. I still believe companies … strive to fulfill the “sows ear to a silk purse” promise to … unlock … any future value to shareholders.
November 23, 2018
Regenerative Medicine Earnings Scorecard - Q3/18 - to date
November 7, 2018
Quarterly (Q3) results special: ATHX, BOLD, BLCM and GBT
November 6, 2018
Quarterly (Q3) results special: IONS, ONCE, QURE and VCEL
September 11, 2018
Regenerative Medicine Earnings Scorecard - Q2/18 - to date
November 3, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 - to date
August 9, 2017
Regenerative Medicine Earnings Scorecard - Q2/2017 - to date
March 10, 2017
Regenerative Medicine Earnings Scorecard - Q4/2016 - to date
November 2, 2016
Regenerative Medicine Earnings Scorecard - Q3/2016 - to date
August 4, 2016
Regenerative Medicine Earnings Scorecard - Q2/2016 - to date
February 9, 2016
Regenerative Medicine Earnings Scorecard - Q4/2015
April 13, 2015
BioLife Solutions (BLFS) Preliminary Q1/15 revenue of $1.5 M
February 18, 2015
Pluristem (PSTI) Q4/14 Earnings: NET LOSS UP +4.9%, LPS FLAT
February 17, 2015
Cesca (KOOL) Q4/14 Earnings: LOSS UP +25%, LPS UP +27%
November 21, 2014
RegMed Q3/14 Earnings Visual Approach
November 20, 2014
VistaGen (OTC: VSTA) Q3/14 Earnings: Loss DOWN 56.5%, LPS* DOWN 58.4%
November 20, 2014
Northwest Bio (NWBO) Q3/14 Earnings: Loss DOWN 18.9%, LPS* DOWN 22.3%
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors